Association of donor and recipient rs1051792 genotypes with risks of GVHD and recurrent malignancy in the combined discovery and replication cohorts
| End point . | Donor . | Recipient . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Grade 2-4 GVHD | 0.96 (0.90-1.01) | .13 | 1.00 (0.94-1.06) | .98 |
| Grade 3-4 GVHD | 0.90 (0.81-1.01) | .05 | 0.96 (0.87-1.07) | .46 |
| NRM after grade 3-4 GVHD | 0.88 (0.76-1.01) | .06 | 0.90 (0.78-1.03) | .12 |
| Chronic GVHD | 1.00 (0.92-1.1) | .99 | 1.03 (0.96-1.11) | .38 |
| Recurrent malignancy | 1.00 (0.92-1.1) | .99 | 1.01 (0.93-1.10) | .78 |
| End point . | Donor . | Recipient . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Grade 2-4 GVHD | 0.96 (0.90-1.01) | .13 | 1.00 (0.94-1.06) | .98 |
| Grade 3-4 GVHD | 0.90 (0.81-1.01) | .05 | 0.96 (0.87-1.07) | .46 |
| NRM after grade 3-4 GVHD | 0.88 (0.76-1.01) | .06 | 0.90 (0.78-1.03) | .12 |
| Chronic GVHD | 1.00 (0.92-1.1) | .99 | 1.03 (0.96-1.11) | .38 |
| Recurrent malignancy | 1.00 (0.92-1.1) | .99 | 1.01 (0.93-1.10) | .78 |
All associations were tested in the allelic model.